P
Patrick M. Reagan
Researcher at University of Rochester Medical Center
Publications - 105
Citations - 7492
Patrick M. Reagan is an academic researcher from University of Rochester Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 19, co-authored 73 publications receiving 4163 citations. Previous affiliations of Patrick M. Reagan include University of Virginia & University of Virginia Health System.
Papers
More filters
Journal ArticleDOI
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu,Frederick L. Locke,Nancy L. Bartlett,Lazaros J. Lekakis,David B. Miklos,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick J. Stiff,Jonathan W. Friedberg,Ian W. Flinn,Andre Goy,Brian T. Hill,Mitchell R. Smith,Abhinav Deol,Umar Farooq,Peter A. McSweeney,Javier Munoz,Irit Avivi,Januario E. Castro,Jason R. Westin,Julio C. Chavez,Armin Ghobadi,Krishna V. Komanduri,Ronald Levy,Eric D. Jacobsen,Thomas E. Witzig,Patrick M. Reagan,Adrian Bot,John J. Rossi,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,David Z. Chang,Jeff Wiezorek,William Y. Go +39 more
TL;DR: Patients with refractory large B‐cell lymphoma who received CAR T‐cell therapy with axi‐cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events.
Journal ArticleDOI
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke,Armin Ghobadi,Caron A. Jacobson,David B. Miklos,Lazaros J. Lekakis,Olalekan O. Oluwole,Yi Lin,Ira Braunschweig,Brian T. Hill,John M. Timmerman,Abhinav Deol,Patrick M. Reagan,Patrick J. Stiff,Ian W. Flinn,Umar Farooq,Andre Goy,Peter A. McSweeney,Javier Munoz,Tanya Siddiqi,Julio C. Chavez,Alex F. Herrera,Nancy L. Bartlett,Jeffrey S. Wiezorek,Lynn Navale,Allen Xue,Yizhou Jiang,Adrian Bot,John M. Rossi,Jenny J. Kim,William Y. Go,Sattva S. Neelapu +30 more
TL;DR: Long-term activity and safety outcomes of the ZUMA-1 study suggest that axicabtagene ciloleucel can induce durable responses and a median overall survival of greater than 2 years, and has a manageable relapsed or refractory disease or relapsed after autologous stem-cell transplantation.
Journal ArticleDOI
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang,Javier Munoz,Andre Goy,Frederick L. Locke,Caron A. Jacobson,Brian T. Hill,John M. Timmerman,Houston Holmes,Samantha Jaglowski,Ian W. Flinn,Peter A. McSweeney,David B. Miklos,John M. Pagel,Marie José Kersten,Noel Milpied,Henry C. Fung,Max S. Topp,Roch Houot,Amer Beitinjaneh,Weimin Peng,Lianqing Zheng,John M. Rossi,Rajul K. Jain,Arati V. Rao,Patrick M. Reagan +24 more
TL;DR: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma, and led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies.
Journal ArticleDOI
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil,Michael D. Jain,Lei Feng,Jay Y. Spiegel,Armin Ghobadi,Yi Lin,Saurabh Dahiya,Matthew A. Lunning,Lazaros J. Lekakis,Patrick M. Reagan,Olalekan O. Oluwole,Joseph P. McGuirk,Abhinav Deol,Alison R. Sehgal,Andre Goy,Brian T. Hill,Khoan Vu,Charalambos Andreadis,Javier Munoz,Jason R. Westin,Julio C. Chavez,Amanda F. Cashen,N. Nora Bennani,Aaron P. Rapoport,Julie M. Vose,David B. Miklos,Sattva S. Neelapu,Frederick L. Locke +27 more
TL;DR: The safety and efficacy of axi-cel in the standard-of-care (SOC) setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.
Journal ArticleDOI
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.
Frederick L. Locke,John M. Rossi,Sattva S. Neelapu,Caron A. Jacobson,David B. Miklos,Armin Ghobadi,Olalekan O. Oluwole,Patrick M. Reagan,Lazaros J. Lekakis,Yi Lin,Marika Sherman,Marc Better,William Y. Go,Jeffrey S. Wiezorek,Allen Xue,Adrian Bot +15 more
TL;DR: Univariable and multivariable analyses indicated that rapid CAR T-cell expansion commensurate with pretreatment tumor burden, the number of CD8 and CCR7+CD45RA+ T cells infused, and host systemic inflammation, were the most significant determining factors for durable response.